Research and Development

The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …

The EMA is launching an adaptive pathway project to bring new medicinal products to market in Europe.  The ADAPT SMART …

Novo Nordisk has announced that the company is investing 500 million Danish kroner (about £48.8 million) in a new 19,000 …

Novo Nordisk has initiated a research collaboration with the Langer Laboratory at the Massachusetts Institute of Technology for what is …

NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS.  …

Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …

One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …

Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …

The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …

Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …

Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine.  The companies plan …

The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …

Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …

Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view …

Clinical technology and services company Mytrus has announced that its software platform for electronic informed consent has received approval for …